EODData

MEMBERSHIP REGISTER LOG IN

FRA, 6OP: OSE IMMUNOTHERAPE.EO -20

26 Mar 2026
LAST:

3.120

CHANGE:
 0.02		OPEN:
3.120		HIGH:
3.120		ASK:
0.000		VOLUME:
500
CHG(%):
0.71		PREV:
3.098		LOW:
3.120		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Mar 263.1203.1203.1203.120500
25 Mar 263.0983.0983.0983.098500
24 Mar 263.3743.3743.3743.374500
23 Mar 263.3423.3423.3423.342500
20 Mar 263.4283.4283.4283.428500
19 Mar 263.4463.4463.4463.4460
18 Mar 263.4883.4883.4883.4880
17 Mar 263.6403.6403.6403.6400
16 Mar 263.6323.6323.6323.6320
13 Mar 263.7403.7403.7403.7400

PROFILE

Name:OSE IMMUNOTHERAPE.EO -20
About:OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Sector:Healthcare
Industry:Biotechnology
Address:22, boulevard Benoni Goulin, Nantes, France, 44200
Website:https://www.ose-immuno.com
ISIN:FR0012127173

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:4.45 
Forward P/E:2.11 
Price to Sales:1.30 
Price to Book:1.66 
Profit Margin:0.45 
Operating Margin:-22.72 
Return on Assets:0.27 
Return on Equity:0.86 
Revenue:83.44M 
EBITDA:34.64M 
Shares:22.89M 
Market Cap:71.42M 

TECHNICAL INDICATORS

MA5:3.274.9%
MA10:3.4310.0%
MA20:3.7420.0%
MA50:4.2536.3%
MA100:4.7853.1%
MA200:5.3069.7%
STO9:4.06 
STO14:2.44 
RSI14:15.41 
WPR14:-97.56 
MTM14:-0.74
ROC14:-0.19 
ATR:0.09 
Week High:3.4510.4%
Week Low:3.100.7%
Month High:4.5646.2%
Month Low:3.1069.7%
Year High:7.17129.6%
Year Low:3.100.7%
Volatility:19.71